Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 30th, there was short interest totaling 115,580 shares, a decline of 66.3% from the October 15th total of 342,847 shares. Based on an average daily volume of 766,639 shares, the days-to-cover ratio is presently 0.2 days. Approximately 5.0% of the shares of the company are sold short.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Arcadia Biosciences in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.
Check Out Our Latest Stock Report on RKDA
Arcadia Biosciences Stock Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The basic materials company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.75. Arcadia Biosciences had a negative net margin of 234.53% and a negative return on equity of 183.50%. The company had revenue of $1.62 million for the quarter, compared to analyst estimates of $2.40 million.
About Arcadia Biosciences
Arcadia Biosciences, Inc. is an agricultural biotechnology company focused on developing and commercializing food ingredients and crop-based products intended to support health and wellness. The company applies plant science and breeding technologies to develop crops with enhanced nutritional characteristics and products designed for consumer and food-industry applications. Its product portfolio has included GoodWheat, a wheat variety developed with increased dietary fiber and other nutritional attributes, as well as GoodHemp, a line of hemp-based food products and ingredients.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
